Previous 10 | Next 10 |
Analysis of results from EMERGE ™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 C ash , cash equivalents and marketable securities of $ 82.1 million as of September 30 , ...
- Credit Suisse - 29 th Annual Healthcare Conference - November 9 th -1 2 th - Stifel 2020 Virtual Healthcare Conference - November 1 6 th -1 8 th SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) ...
Satsuma shares have collapsed in value after the company's only drug candidate STS101 failed a late-stage trial in acute migraine treatment. The share price fell from $24, to $4, and most analysts have set a price target of $4. The EMERGE trial was not a complete blowout. STS101 -...
Evercore ISI's newest update to its best SMID "core" ideas list - resumed last month with 19 new names - adds three new tickers to the firm's very best small and mid-cap ideas, along with removing one. More news on: Bristow Group Inc., The Timken Company, ChampionX Corporation, Notable C...
Novus Therapeutics (NASDAQ: NVUS ) -17% . More news on: Novus Therapeutics, Inc., Nano-X Imaging Ltd., Plus Therapeutics, Inc., Stocks on the move, , Read more ...
Satsuma reports disappointing top-line data for Phase 3 trial Satsuma Pharmaceuticals, Inc. (STSA) reported top-line results from its EMERGE efficacy trial assessing STS101 powder as an acute treatment for migraine. The top-line data showed favorable numerical differences for STS101 3.9...
Gainers: A-Mark Precious Metals (NASDAQ: AMRK ) +23% . More news on: A-Mark Precious Metals, Inc., Natural Health Trends Corp., Biofrontera AG, Stocks on the move, , Read more ...
Satsuma Pharmaceuticals (NASDAQ: STSA ) slips 4% premarket after downgrades by Credit Suisse, Mizuho and Leeirk . More news on: Satsuma Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Evofem Biosciences (NASDAQ: EVFM ) -14% . More news on: Evofem Biosciences, Inc., Amyris, Inc., Muscle Maker, Inc., , Stocks on the move, Read more ...
Gainers: Yield10 Bioscience (NASDAQ: YTEN ) +60% . More news on: Yield10 Bioscience, Inc., Renren Inc., Virtusa Corporation, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Satsuma Pharmaceuticals Inc. Company Name:
STSA Stock Symbol:
NYSE Market:
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc...
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society ...
NEW YORK, NY / ACCESSWIRE / May 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hoth Therapeutics, Inc. (NASDAQ:HOTH)'s...